News
ESC22: Despite trial misses, Bayer preps phase 3 for asundex...
Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.
